BioCentury
ARTICLE | Company News

Takeda proposes divestment of Shire GI candidate, announces loans

November 2, 2018 8:01 PM UTC

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said it proposed to the European Commission a potential divestment of Crohn’s disease and ulcerative colitis candidate SHP647 once it completes its acquisition of Shire plc (LSE:SHP; NASDAQ:SHPG). The move would remedy a potential future overlap between the product and Takeda’s marketed Crohn’s and UC drug Entyvio vedolizumab.

In May, Shire accepted Takeda’s proposed takeout offer, which would increase Takeda’s U.S. share of revenues from 34% to 48% and nearly double its overall revenues (see “Takeda Hits the Gas”)...